Home › Companies › Immunovant, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Immunovant, Inc.’s Form 8-K, filed August 28, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of August 27, 2025: 5 items on Immunovant, Inc.’s Form 8-K, filed August 28, 2025: 2 elected · 2 approved · 1 passed (calculated).
Notable dissent: 1 director (10.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Two Seas Capital LP (13F, 2.2%, as of September 30, 2026)
Explore Immunovant, Inc. in the interactive database Compare manager voting policies
These tallies are Immunovant, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed August 28, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jacob Bauer | 152,051,231 | -- | -- | 8,193,169 | 5,641,080 | 95% | Passed (calculated) | — |
| Elect Director: Douglas Hughes | 143,417,281 | -- | -- | 16,827,119 | 5,641,080 | 89% | Elected | — |
| Elect Director: Robert Susman | 159,234,780 | -- | -- | 1,009,620 | 5,641,080 | 99.4% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 165,422,634 | 7,237 | 455,609 | -- | -- | 99.9% | Approved | — |
| 3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers | 158,995,232 | 1,244,731 | 4,437 | -- | 5,641,080 | 99.2% | Approved | — |
Source: Immunovant, Inc., Form 8-K, filed with the SEC on August 28, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
186 asset managers disclosed a vote on at least one Immunovant, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Jacob Bauer
Immunovant, Inc.’s own tally for this item (“Elect Director: Jacob Bauer”): 152,051,231 for, 8,193,169 withheld, per its Form 8-K filed August 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 21,243,926 for, 4,845,150 withheld, 3,421 abstained, 54 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 11,160,985 | 0 | 0 | 0 | For |
| Vanguard | 5,609,772 | 0 | 0 | 600 | For |
| T. Rowe Price | 0 | 0 | 0 | 4,619,213 | Withhold |
| BlackRock | 2,257,621 | 0 | 0 | 0 | For |
| Charles Schwab | 646,293 | 0 | 0 | 0 | For |
| State Street | 531,050 | 0 | 0 | 0 | For |
| Morgan Stanley | 170,821 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 122,100 | Withhold |
| Equitable | 116,028 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,927 | 0 | 0 | 0 | For |
| Nuveen | 72,220 | 0 | 0 | 0 | For |
| Lincoln Financial | 52,500 | 0 | 0 | 3,450 | Mixed |
| Dimensional | 0 | 0 | 0 | 50,221 | Withhold |
| Northwestern Mutual | 0 | 0 | 0 | 48,710 | Withhold |
| ProShares | 42,829 | 0 | 0 | 0 | For |
| Global X | 37,440 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 35,423 | 0 | 0 | 0 | For |
| Victory Capital | 31,999 | 0 | 0 | 0 | For |
| Guggenheim | 29,490 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,937 | 0 | 0 | 0 | For |
| TIAA | 24,351 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 21,797 | 0 | 0 | 0 | For |
| Pacific Life | 20,561 | 0 | 0 | 0 | For |
| Brighthouse | 17,739 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Prior year: 73.7% for (August 12, 2024 meeting) ▲ 15.8 pts
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Douglas Hughes
Immunovant, Inc.’s own tally for this item (“Elect Director: Douglas Hughes”): 143,417,281 for, 16,827,119 withheld, per its Form 8-K filed August 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the " Board " ), until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, by the following vote…”
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 20,707,374 for, 2,983,925 withheld, 2,401,199 abstained, 54 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 9,529,660 | 0 | 0 | 1,631,325 | Mixed |
| Vanguard | 5,610,373 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,608,896 | 0 | 0 | 10,317 | For |
| BlackRock | 0 | 0 | 2,257,621 | 0 | Abstain |
| Charles Schwab | 646,293 | 0 | 0 | 0 | For |
| State Street | 1,640 | 0 | 0 | 529,410 | Withhold |
| Morgan Stanley | 170,821 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 122,100 | Withhold |
| Equitable | 13,703 | 0 | 0 | 102,325 | Mixed |
| Goldman Sachs | 0 | 0 | 0 | 111,883 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 97,927 | 0 | Abstain |
| Nuveen | 0 | 0 | 0 | 72,220 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 55,950 | Withhold |
| Dimensional | 0 | 0 | 0 | 50,221 | Withhold |
| Northwestern Mutual | 48,710 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 42,829 | Withhold |
| Global X | 37,440 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 0 | 0 | 35,423 | 0 | Abstain |
| Victory Capital | 0 | 0 | 0 | 31,999 | Withhold |
| Guggenheim | 0 | 0 | 0 | 29,490 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 25,937 | Withhold |
| TIAA | 0 | 0 | 0 | 24,351 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 21,797 | Withhold |
| Pacific Life | 0 | 0 | 0 | 20,561 | Withhold |
| Brighthouse | 0 | 0 | 0 | 17,739 | Withhold |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99.4% Majority: yes · of votes cast
Description as filed by funds: To elect as directors the three nominees named in the Company's proxy statement, each to hold office until our 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Robert Susman
Immunovant, Inc.’s own tally for this item (“Elect Director: Robert Susman”): 159,234,780 for, 1,009,620 withheld, per its Form 8-K filed August 28, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors Jacob Bauer, Douglas Hughes and Robert Susman were each elected to serve as a member of Immunovant's Board of Directors (the " Board " ), until the 2026 Annual Meeting of Stockholders and until their successors are duly elected and qualified, by the following vote…”
Support: 99.4% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 26,092,497 for, 54 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 11,160,985 | 0 | 0 | 0 | For |
| Vanguard | 5,610,373 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,619,213 | 0 | 0 | 0 | For |
| BlackRock | 2,257,621 | 0 | 0 | 0 | For |
| Charles Schwab | 646,293 | 0 | 0 | 0 | For |
| State Street | 531,050 | 0 | 0 | 0 | For |
| Morgan Stanley | 170,821 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 122,100 | 0 | 0 | 0 | For |
| Equitable | 116,028 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,927 | 0 | 0 | 0 | For |
| Nuveen | 72,220 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,950 | 0 | 0 | 0 | For |
| Dimensional | 50,221 | 0 | 0 | 0 | For |
| Northwestern Mutual | 48,710 | 0 | 0 | 0 | For |
| ProShares | 42,829 | 0 | 0 | 0 | For |
| Global X | 37,440 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 35,423 | 0 | 0 | 0 | For |
| Victory Capital | 31,999 | 0 | 0 | 0 | For |
| Guggenheim | 29,490 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,937 | 0 | 0 | 0 | For |
| TIAA | 24,351 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 21,797 | 0 | 0 | 0 | For |
| Pacific Life | 20,561 | 0 | 0 | 0 | For |
| Brighthouse | 17,739 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Combines 6 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Prior year: 97.5% for (August 12, 2024 meeting) ▲ 1.7 pts
Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of our named executive officers.
Immunovant, Inc.’s own tally for this item (“3. Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers”): 158,995,232 for, 1,244,731 against — passed, per its Form 8-K filed August 28, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 - Approval, on a Non-Binding Advisory Basis, of the Compensation of Immunovant's Named Executive Officers The stockholders approved, on a non-binding advisory basis, the compensation of Immunovant ' s named executive officers, as disclosed in the Proxy Statement, including the compensati…”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 11,160,985 | 0 | 0 | 0 | For |
| Vanguard | 5,610,368 | 4 | 0 | 0 | For |
| T. Rowe Price | 4,619,213 | 0 | 0 | 0 | For |
| BlackRock | 2,257,621 | 0 | 0 | 0 | For |
| Charles Schwab | 646,293 | 0 | 0 | 0 | For |
| State Street | 530,325 | 725 | 0 | 0 | For |
| Morgan Stanley | 170,821 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 122,100 | 0 | 0 | 0 | For |
| Equitable | 116,028 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,927 | 0 | 0 | 0 | For |
| Nuveen | 72,220 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,950 | 0 | 0 | 0 | For |
| Dimensional | 50,221 | 0 | 0 | 0 | For |
| Northwestern Mutual | 48,710 | 0 | 0 | 0 | For |
| ProShares | 42,829 | 0 | 0 | 0 | For |
| Global X | 37,440 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 35,423 | 0 | 0 | 0 | For |
| Victory Capital | 31,999 | 0 | 0 | 0 | For |
| Guggenheim | 29,490 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,937 | 0 | 0 | 0 | For |
| TIAA | 24,351 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 21,797 | 0 | 0 | 0 | For |
| Pacific Life | 20,561 | 0 | 0 | 0 | For |
| Brighthouse | 17,739 | 0 | 0 | 0 | For |
Fund voting reports, all 52 managers: 26,090,858 for, 1,610 against, 54 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 16,492,231 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 9,500,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 7,059,181 | 0 | 0 | 0 | For |
| Point72 | 3,375,597 | 0 | 0 | 0 | For |
| ARMISTICE CAPITAL, LLC | 3,303,973 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,811,967 | 0 | 0 | 0 | For |
| BlackRock | 1,690,377 | 926 | 0 | 0 | For |
| State Street | 1,540,749 | 725 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,063,119 | 0 | 0 | 0 | For |
| Aberdeen | 844,705 | 0 | 0 | 0 | For |
| Charles Schwab | 661,350 | 0 | 0 | 0 | For |
| Two Seas Capital LP | 543,974 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 524,352 | 0 | 0 | 0 | For |
| Morgan Stanley | 494,010 | 0 | 0 | 0 | For |
| CANADA PENSION PLAN INVESTMENT BOARD | 414,800 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 337,473 | 0 | 0 | 0 | For |
| Northern Trust | 299,789 | 0 | 0 | 0 | For |
| Logos Global Management LP | 275,000 | 0 | 0 | 0 | For |
| Woodline Partners LP | 246,874 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 221,962 | 0 | 0 | 0 | For |
| Goldman Sachs | 202,539 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 195,727 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 191,493 | 0 | 0 | 0 | For |
| HighVista Strategies LLC | 182,808 | 0 | 0 | 0 | For |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 159,091 | 0 | 0 | 0 | For |
Institutional-manager reports, all 152 managers: 53,384,690 for, 204,831 against, 71,471 abstained, 54 not voted. Showing the 25 largest; every one is in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Prior year: 100.0% for (August 12, 2024 meeting) unchanged
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending March 31, 2026.
Immunovant, Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 165,422,634 for, 7,237 against — passed, per its Form 8-K filed August 28, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection of Independent Registered Public Accounting Firm The stockholders ratified the selection by the Audit Committee of the Board of Ernst & Young LLP as Immunovant's independent registered public accounting firm for the fiscal year ending March 31, 2026, by th…”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 53 asset managers below reported 26,092,497 for, 54 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 11,160,985 | 0 | 0 | 0 | For |
| Vanguard | 5,610,373 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,619,213 | 0 | 0 | 0 | For |
| BlackRock | 2,257,621 | 0 | 0 | 0 | For |
| Charles Schwab | 646,293 | 0 | 0 | 0 | For |
| State Street | 531,050 | 0 | 0 | 0 | For |
| Morgan Stanley | 170,821 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 122,100 | 0 | 0 | 0 | For |
| Equitable | 116,028 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,883 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 97,927 | 0 | 0 | 0 | For |
| Nuveen | 72,220 | 0 | 0 | 0 | For |
| Lincoln Financial | 55,950 | 0 | 0 | 0 | For |
| Dimensional | 50,221 | 0 | 0 | 0 | For |
| Northwestern Mutual | 48,710 | 0 | 0 | 0 | For |
| ProShares | 42,829 | 0 | 0 | 0 | For |
| Global X | 37,440 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 35,423 | 0 | 0 | 0 | For |
| Victory Capital | 31,999 | 0 | 0 | 0 | For |
| Guggenheim | 29,490 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 25,937 | 0 | 0 | 0 | For |
| TIAA | 24,351 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 21,797 | 0 | 0 | 0 | For |
| Pacific Life | 20,561 | 0 | 0 | 0 | For |
| Brighthouse | 17,739 | 0 | 0 | 0 | For |
Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 171,069,176 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 6.52% |
| 2 | Vanguard | 3.28% |
| 3 | T. Rowe Price | 2.70% |
| 4 | BlackRock | 1.32% |
| 5 | Charles Schwab | 0.38% |
| 6 | State Street | 0.31% |
| 7 | Morgan Stanley | 0.10% |
| 8 | Delaware/Macquarie | 0.07% |
| 9 | Equitable | 0.07% |
| 10 | Goldman Sachs | 0.07% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 9.64% |
| 2 | Deep Track Capital, LP | 5.55% |
| 3 | T. Rowe Price | 4.13% |
| 4 | Point72 | 1.97% |
| 5 | ARMISTICE CAPITAL, LLC | 1.93% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.06% |
| 7 | BlackRock | 0.99% |
| 8 | State Street | 0.90% |
| 9 | PICTET ASSET MANAGEMENT SA | 0.62% |
| 10 | Aberdeen | 0.49% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Roivant Sciences Ltd. | 113,327,007 | — | Proxy statement (DEF 14A), proxy filed July 22, 2026 |
| FMR (Fidelity) | 16,947,888 | — | Form 13F, quarter ended March 31, 2026 |
| FMR LLC | 14,729,555 | — | Proxy statement (DEF 14A), proxy filed July 22, 2026 |
| Vanguard Group | 7,779,314 | — | Form 13F, quarter ended March 31, 2026 |
| BlackRock | 6,574,497 | — | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 4,846,385 | — | Form 13F, quarter ended March 31, 2026 |
| State Street | 4,537,929 | — | Form 13F, quarter ended March 31, 2026 |
| Geode Capital | 2,092,102 | — | Form 13F, quarter ended March 31, 2026 |
| Frank M. Torti | 1,954,091 | — | Proxy statement (DEF 14A), proxy filed July 22, 2026 |
| Goldman Sachs | 1,785,107 | — | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 171,069,176 shares outstanding, as reported by Immunovant, Inc. on its Form 10-Q dated June 30, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Immunovant, Inc.'s shareholder meeting held August 27, 2025, in the 2025-2026 proxy season, 186 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,094 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of our named executive officers. — Immunovant, Inc.'s filing reports the proposal as approved, with 99.2% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Immunovant, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on August 28, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Immunovant, Inc.’s 10-Q dated June 30, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Immunovant, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Immunovant (IMVT) 2025 Annual Meeting (2025-2026 season): Vote Results”, https://proxyvotesnow.com/company/immunovant-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.